Author Takaki, Akinobu|
Published Date 1994-03-31
Publication Title
Content Type Thesis or Dissertation
JaLCDOI 10.18926/AMO/52790
FullText URL 68_4_243.pdf
Author Wada, Nozomu| Yasunaka, Tetsuya| Ikeda, Fusao| Nishina, Sohji| Korenaga, Masaaki| Hino, Keisuke| Fujioka, Shin-ichi| Osawa, Toshiya| Itoshima, Tatsuya| Kawanaka, Miwa| Yamada, Gotaro| Kariyama, Kazuya| Takayama, Hiroki| Kubota, Junichi| Morimoto, Yoichi| Mizushima, Takaaki| Yamashita, Haruhiko| Tanioka, Hiroaki| Negoro, Yuji| Toshimori, Junichi| Kobashi, Haruhiko| Hirano, Atsushi| Itano, Yasuo| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract Hepatitis B virus (HBV) is one of the major viruses causing acute hepatitis. Recently, the incidence of acute hepatitis with genotype A has been increasing in Japan. The aim of this study was to investigate acute hepatitis B (AHB) in Okayama prefecture, with special attention to HBV genotype A. AHB patients who visited one of 12 general hospitals in Okayama prefecture between 2006 and 2010 were retrospectively analyzed. Over the course of the study period, 128 patients were diagnosed with AHB. Sexual transmission was supposed in the majority of patients (78 patients, 61%), including 59 (76%) having sex with heterosexual partners. The genotypes of HBV were assessed in 90 patients (70%), of whom 27 patients were infected with genotype A, 5 with genotype B, and 58 with genotype C. The prevalence of genotype A was significantly higher among male patients (28.7%), aged 20-29 (35.6%, p<0.01), among men who had sex with men (100%, p<0.005), and among patients having sex with unspecified partners (44.8%, p<0.005). Genotype A was not a significant factor associated with delayed HBsAg disappearance. Caution should be exercised with regard to sexually transmissible diseases in order to slow the pandemic spread of AHB due to genotype A.
Keywords acute hepatitis hepatitis B virus
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2014-08
Volume volume68
Issue issue4
Publisher Okayama University Medical School
Start Page 243
End Page 247
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 25145410
Web of Science KeyUT 000340687500006
FullText URL fulltext.pdf
Author Uchida, Daisuke| Takaki, Akinobu| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Onishi, Hideki| Okada, Hiroyuki|
Keywords oxidative stress chronic hepatitis hepatocellular carcinoma
Published Date 2020-05-28
Publication Title Nutrients
Volume volume12
Issue issue6
Publisher MDPI
Start Page 1576
ISSN 2072-6643
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by the authors.
File Version publisher
PubMed ID 32481552
DOI 10.3390/nu12061576
Web of Science KeyUT 000554005200001
Related Url isVersionOf https://doi.org/10.3390/nu12061576
JaLCDOI 10.18926/AMO/52898
FullText URL 68_5_291.pdf
Author Tsuzaki, Ryuichiro| Takaki, Akinobu| Yagi, Takahito| Ikeda, Fusao| Koike, Kazuko| Iwasaki, Yoshiaki| Shiraha, Hidenori| Miyake, Yasuhiro| Sadamori, Hiroshi| Shinoura, Susumu| Umeda, Yuzo| Yoshida, Ryuichi| Nobuoka, Daisuke| Utsumi, Masashi| Nakayama, Eiichi| Fujiwara, Toshiyoshi| Yamamoto, Kazuhide|
Abstract It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At>3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.
Keywords interferon gamma ELISPOT assay single nucleotide polymorphisms dendritic cell CD4 T cell
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2014-10
Volume volume68
Issue issue5
Publisher Okayama University Medical School
Start Page 291
End Page 302
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 25338486
Web of Science KeyUT 000343269300006
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/53129
JaLCDOI 10.18926/AMO/53520
FullText URL 69_3_137.pdf
Author Seki, Hiroyuki| Ikeda, Fusao| Nanba, Shintaro| Moritou, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Nakamura, Minoru| Yamamoto, Kazuhide|
Abstract A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.
Keywords primary biliary cirrhosis keratin 7 hepatic failure
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-06
Volume volume69
Issue issue3
Publisher Okayama University Medical School
Start Page 137
End Page 144
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26101189
Web of Science KeyUT 000356903000002
JaLCDOI 10.18926/AMO/53558
FullText URL 69_4_219.pdf
Author Toshimori, Junichi| Nouso, Kazuhiro| Nakamura, Shinichiro| Wada, Nozomu| Morimoto, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Kuwaki, Kenji| Ohnishi, Hideki| Ikeda, Fusao| Shiraha, Hidenori| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n=397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing factors for overall recurrence and local recurrence in the context of tumor location and complications were examined. Local recurrence was observed for 113 of the 1,455 nodules. The 1-, 3- and 5-year local recurrence rates were 2.2オ, 7.4オ and 9.5オ, respectively. A multivariate Cox proportional hazard analysis revealed that large tumor size (>2cm), tumor location (adjacent to the major portal branch or hepatic vein), and small ablated margin (<3mm) were independent predisposing factors for local recurrence after RFA (HR=1.70-2.81). Tumor location (adjacent to the major portal branch, hepatic vein, or diaphragm) was also revealed as a risk factor for liver damage due to RFA. HCC adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recurrence and for complications;therefore, special precautions are necessary when applying RFA to HCC near vessels even when the tumors are located at an easy-to-puncture site.
Keywords hepatocellular carcinoma radiofrequency ablation ablated margin tumor location
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-08
Volume volume69
Issue issue4
Publisher Okayama University Medical School
Start Page 219
End Page 226
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26289913
Web of Science KeyUT 000365519100005
JaLCDOI 10.18926/AMO/53560
FullText URL 69_4_237.pdf
Author Nanba, Shintarou| Ikeda, Fusao| Fujioka, Shin-ichi| Araki, Yasuyuki| Takaguchi, Kouichi| Hashimoto, Noriaki| Seki, Hiroyuki| Takaki, Akinobu| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
Abstract The effectiveness of extending treatment duration as response guided therapy was previously reported for chronic hepatitis C (CHC) genotype 1, but is still controversial for genotype 2. The present study is a retrospective cohort study to investigate the effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the timing at which patients obtained undetectable HCV RNA. A total of 306 patients who obtained undetectable HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled. Rapid virological response (RVR) to standard therapy was achieved by 122 patients (51オ), and 89オ of them obtained sustained virological response (SVR), while 69オ of non-RVR patients achieved SVR. Non-RVR patients with undetectable HCV RNA at week 8, and insufficient adherence<80オ pegylated interferon and ribavirin during the first 24 weeks, significantly improved their SVR rate by extended therapy. Among patients receiving extended therapy, drug adherences did not differ between SVR and non-SVR patients, indicating that extending treatment duration might compensate for insufficient antiviral effects due to insufficient drug adherences. This finding might be useful in creating a guideline for extending treatment duration for patients with CHC genotype 2.
Keywords hepatitis C virus interferon genotype 2 response-guided therapy
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2015-08
Volume volume69
Issue issue4
Publisher Okayama University Medical School
Start Page 237
End Page 244
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2015 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26289915
Web of Science KeyUT 000365519100007
JaLCDOI 10.18926/AMO/53996
FullText URL 70_1_1.pdf
Author Yasunaka, Tetsuya| Ikeda, Fusao| Wada, Nozomu| Morimoto, Yuki| Fujioka, Shin-ichi| Toshimori, Junichi| Kobashi, Haruhiko| Kariyama, Kazuya| Morimoto, Yoichi| Takayama, Hiroki| Seno, Tomonori| Takaguchi, Koichi| Moriya, Akio| Miyatake, Hirokazu| Okamoto, Ryoichi| Yabushita, Kazuhisa| Takaki, Akinobu| Yamamoto, Kazuhide|
Abstract Chronic hepatitis B (CHB) leads to cirrhosis and hepatocellular carcinoma (HCC). With a cohort of 1,206 CHB patients who visited Okayama University Hospital and related hospitals in 2011 and 2012, we compared the incidence rates of HCC among the patients grouped by age, hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and treatment. HCCs were observed in 115 patients with the median observation period of 1,687 days. Among the HCC patients aged ≥ 35 years, HBV DNA ≥ 4 log copies/mL and positive HBeAg at diagnosis (n=184), the HCC incidence rate was 8.4% at 5 years in the entecavir (ETV)-treated patients, 21.8% in the lamivudine (LVD)-treated patients, and 26.4% among the patients not treated with drugs. The cumulative HCC incidence was significantly reduced in the ETV-treated patients compared to those treated with LVD or not treated (p=0.013). Among the patients aged ≥ 35 years with HBV DNA ≥ 4 log copies/mL and negative HBeAg (n=237), the cumulative HCC incidence was 14.6% in 5 years in ETV group and 13.9% among those not treated with a drug (p>0.05). Only small numbers of HCCs occurred in other patients. In CHB patients aged≥35 years with HBV DNA ≥4 log copies/mL and positive HBeAg, ETV treatment is recommended for the suppression of HCC development.
Keywords entecavir hepatitis B virus lamivudine hepatocellular carcinoma
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2016-02
Volume volume70
Issue issue1
Publisher Okayama University Medical School
Start Page 1
End Page 12
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2016 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 26899604
Web of Science KeyUT 000371288700001
JaLCDOI 10.18926/AMO/55435
FullText URL 71_5_381.pdf
Author Yoshida, Kazuhiro| Umeda, Yuzo| Takaki, Akinobu| Nagasaka, Takeshi| Yoshida, Ryuichi| Nobuoka, Daisuke| Kuise, Takashi| Takagi, Kosei| Yasunaka, Tetsuya| Okada, Hiroyuki| Yagi, Takahito| Fujiwara, Toshiyoshi|
Abstract Determining the indications for and timing of liver transplantation (LT) for acute liver failure (ALF) is essential. The King’s College Hospital (KCH) guidelines and Japanese guidelines are used to predict the need for LT and the outcomes in ALF. These guidelines’ accuracy when applied to ALF in different regional and etiological backgrounds may differ. Here we compared the accuracy of new (2010) Japanese guidelines that use a simple scoring system with the 1996 Japanese guidelines and the KCH criteria for living donor liver transplantation (LDLT). We retrospectively analyzed 24 adult ALF patients (18 acute type, 6 sub-acute type) who underwent LDLT in 1998-2009 at our institution. We assessed the accuracies of the 3 guidelines’ criteria for ALF. The overall 1-year survival rate was 87.5%. The new and previous Japanese guidelines were superior to the KCH criteria for accurately predicting LT for acute-type ALF (72% vs. 17%). The new Japanese guidelines could identify 13 acute-type ALF patients for LT, based on the timing of encephalopathy onset. Using the previous Japanese guidelines, although the same 13 acute-type ALF patients (72%) had indications for LT, only 4 patients were indicated at the 1st step, and it took an additional 5 days to decide the indication at the 2nd step in the other 9 cases. Our findings showed that the new Japanese guidelines can predict the indications for LT and provide a reliable alternative to the previous Japanese and KCH guidelines.
Keywords living donor liver transplantation acute liver failure fulminant hepatic failure
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2017-10
Volume volume71
Issue issue5
Publisher Okayama University Medical School
Start Page 381
End Page 390
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2017 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 29042695
JaLCDOI 10.18926/AMO/60364
FullText URL 74_4_275.pdf
Author Muro, Taiko| Nakamura, Shinichiro| Takaki, Akinobu| Onishi, Hideki| Wada, Nozomu| Yasunaka, Tetsuya| Uchida, Daisuke| Oyama, Atsushi| Adachi, Takuya| Shiraha, Hidenori| Okada, Hiroyuki|
Abstract Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is a promising method for controlling tumors, although it does not entirely eliminate recurrence. Oxidative stress is associated with the progression of hepatocarcinogenesis, while also acting as an anticancer response. The objective of the present study was to investigate the factors influencing post-RFA outcomes. We recruited 235 newly diagnosed HCC patients who received RFA for single tumors. The patients with recurrence were sub-grouped into early and segmental recurrence groups. The characteristics of the sub-grouped patients were evaluated, including by measuring oxidative stress marker reactive oxygen metabolites and antioxidant marker OXY-adsorbent tests. The factors associated with poor survival were a high Child-Pugh score and early recurrence within 2 years in the same segment. The patients who experienced recurrence within 2 years in the same segment showed a larger tumor diameter than did others. According to a multivariate analysis, the OXY values were also significantly low in these patients. In conclusion, maintaining the antioxidant reservoir function with a high OXY value might be necessary to prevent early recurrence within the RFA-treated segment.
Keywords oxidative stress hepatocellular carcinoma recurrence, radiofrequency ablation
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2020-08
Volume volume74
Issue issue4
Publisher Okayama University Medical School
Start Page 275
End Page 283
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 32843758
Web of Science KeyUT 000562508700002
NAID 120006880203
Author Matsuo, Noriyuki| Shiraha, Hidenori| Fujikawa, Tatsuya| Takaoka, Nobuyuki| Ueda, Naoki| Tanaka, Shigetomi| Nishina, Shinichi| Nakanishi, Yutaka| Uemura, Masayuki| Takaki, Akinobu| Nakamura, Shinichiro| Kobayashi, Yoshiyuki| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide|
Published Date 2009-07-18
Publication Title BMC Cancer
Volume volume9
Content Type Journal Article
Author Nakanishi, Yutaka| Shiraha, Hidenori| Nishina, Shin-ichi| Tanaka, Shigetomi| Matsubara, Minoru| Horiguchi, Shigeru| Iwamuro, Masaya| Takaoka, Nobuyuki| Uemura, Masayuki| Kuwaki, Kenji| Hagihara, Hiroaki| Toshimori, Junichi| Ohnishi, Hideki| Takaki, Akinobu| Nakamura, Shinichiro| Kobayashi, Yoshiyuki| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide|
Published Date 2011-01-04
Publication Title BMC Cancer
Volume volume11
Content Type Journal Article
FullText URL JGastroenterol_54_11_1019.pdf Table.pdf Figure 1.jpg Figure 2.jpg Figure 3A.tif Figure 3B.tif supplemental figure 1.jpg
Author Matsumoto, Kazuyuki| Ohara, Toshiaki| Fujisawa, Masayoshi| Takaki, Akinobu| Takahara, Masahiro| Tanaka, Noriyuki| Kato, Hironari| Horiguchi, Shigeru| Yoshida, Ryuichi| Umeda, Yuzo| Fushimi, Soichiro| Yagi, Takahito| Matsukawa, Akihiro| Okada, Hiroyuki|
Keywords Immunohistochemistry PD-L1 Pancreatic cancer
Note This fulltext will be available in Apr 2020|
Published Date 2019-04-29
Publication Title Journal of Gastroenterology
Volume volume54
Issue issue11
Start Page 1019
End Page 1028
ISSN 09441174
NCID AA10988015
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
File Version author
PubMed ID 31032528
DOI 10.1007/s00535-019-01586-6
Web of Science KeyUT 000492169400008
Related Url isVersionOf https://doi.org/10.1007/s00535-019-01586-6
FullText URL fulltext.pdf
Author Yamamoto, Shumpei| Onishi, Hideki| Takaki, Akinobu| Oyama, Atsushi| Adachi, Takuya| Wada, Nozomu| Sakata, Masahiro| Yasunaka, Tetsuya| Shiraha, Hidenori| Okada, Hiroyuki|
Keywords Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Low-dose cisplatin plus 5-fluorouracil alpha-Fetoprotein Des-gamma-carboxy prothrombin
Published Date 2020-04-21
Publication Title Gastrointestinal Tumors
Volume volume7
Issue issue3
Publisher Karger
Start Page 83
End Page 92
ISSN 2296-3774
NCID AA12665877
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2020 The Author(s)
File Version publisher
DOI 10.1159/000506941
Web of Science KeyUT 000551254300003
Related Url isVersionOf https://doi.org/10.1159/000506941
JaLCDOI 10.18926/AMO/52894
FullText URL 68_5_263.pdf
Author Namba, Shihoko| Miyake, Kayoko| Ikeda, Fusao| Hazama, Tomoko| Hitobe, Yu| Yamasaki, Noriko| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
Abstract Nursing support might help patients with chronic hepatitis C (CHC) remain in good mental and physical condition during interferon (IFN) therapy. However, the effects of nursing support have not been studied adequately in this context. This case-control study evaluated the effects of nursing support during IFN therapy. Twenty-four CHC patients who received pegylated IFN and ribavirin were enrolled. Nurses advised patients on the maintenance of their mental and physical condition at weekly visits, based on the results of written questionnaires. An additional 24 patients who received IFN therapy without nursing support and who were matched for age, sex, platelet count, viral serogroup and IFN regimen were selected with propensity score matching as controls. The patients with nursing support during IFN therapy achieved higher sustained virological responses (79%) than those without nursing support (58%). Adherence to the IFN and ribavirin regimens at 24 weeks of therapy were slightly higher in the patients with nursing support than those without it, but these differences were not statistically significant. Adherence to ribavirin after 24 weeks of therapy was significantly higher in those with nursing support than those without it (93% and 66%, p=0.045). These results suggested that nursing support services could contribute to the virological responses of CHC patients by promoting drug-regimen adherence.
Keywords chronic hepatitis C nursing support interferon therapy
Amo Type Original Article
Publication Title Acta Medica Okayama
Published Date 2014-10
Volume volume68
Issue issue5
Publisher Okayama University Medical School
Start Page 263
End Page 268
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 25338482
Web of Science KeyUT 000343269300002
Author Tanaka, Shigetomi| Shiraha, Hidenori| Nakanishi, Yutaka| Nishina, Shin-Ichi| Matsubara, Minoru| Horiguchi, Shigeru| Takaoka, Nobuyuki| Iwamuro, Masaya| Kataoka, Junro| Kuwaki, Kenji| Hagihara, Hiroaki| Toshimori, Junichi| Ohnishi, Hideki| Takaki, Akinobu| Nakamura, Shinichiro| Nouso, Kazuhiro| Yagi, Takahito| Yamamoto, Kazuhide|
Published Date 2012-12-01
Publication Title International Journal of Cancer
Volume volume131
Issue issue11
Content Type Journal Article
FullText URL fulltext.pdf
Author Yamamoto, Shumpei| Onishi, Hideki| Oyama, Atsushi| Takaki, Akinobu| Okada, Hiroyuki|
Keywords colitis hepatic arterial infusion chemotherapy cisplatin
Published Date 2020-01-01
Publication Title Internal Medicine
Volume volume59
Issue issue1
Publisher The Japanese Society of Internal Medicine
Start Page 69
End Page 75
ISSN 0918-2918
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2020 by The Japanese Society of Internal Medicine
File Version publisher
PubMed ID 32611959
DOI 10.2169/internalmedicine.3340-19
Related Url isVersionOf https://doi.org/10.2169/internalmedicine.3340-19
FullText URL fulltext.pdf
Author Adachi, Takuya| Takeuchi, Yasuto| Takaki, Akinobu| Oyama, Atsushi| Wada, Nozomu| Onishi, Hideki| Shiraha, Hidenori| Okada, Hiroyuki|
Keywords tolvaptan liver cirrhosis ascites
Published Date 2021-05-25
Publication Title International Journal of Molecular Sciences
Volume volume22
Issue issue11
Publisher MDPI
Start Page 5582
ISSN 1422-0067
Content Type Journal Article
language English
OAI-PMH Set 岡山大学
Copyright Holders © 2021 by the authors.
File Version publisher
PubMed ID 34070416
NAID 120007089839
DOI 10.3390/ijms22115582
Web of Science KeyUT 000660134900001
Related Url isVersionOf https://doi.org/10.3390/ijms22115582
Author Nishimura, Mamoru| Takaki, Akinobu| Tamaki, Naofumi| Maruyama, Takayuki| Onishi, Hideki| Kobayashi, Sayo| Nouso, Kazuhiro| Yasunaka, Tetsuya| Koike, Kazuko| Hagihara, Hiroaki| Kuwaki, Kenji| Nakamura, Shinichiro| Ikeda, Fusao| Iwasaki, Yoshiaki| Tomofuji, Takaaki| Morita, Manabu| Yamamoto, Kazuhide|
Published Date 2013-01-30
Publication Title Hepatology Research
Volume volume43
Issue issue10
Content Type Journal Article
JaLCDOI 10.18926/AMO/52145
FullText URL 68_1_53.pdf
Author Terasaka, Tomohiro| Ueta, Eijiro| Ebara, Hirotaka| Waseda, Koichi| Hanayama, Yoshihisa| Takaki, Akinobu| Kawabata, Tomoko| Sugiyama, Hitoshi| Hidan, Ko| Otsuka, Fumio|
Abstract A 64-year-old man suffering polyarthralgia and bone pain was referred to our hospital. Renal dysfunction, hypophosphatemia and increased levels of bone alkaline phosphatase were found. The patientʼs serum creatinine level had gradually increased after the initiation of adefovir dipivoxil administration for hepatitis B. In agreement with multifocal uptakes of bone scintigraphy, iliac bone biopsy revealed an abnormal increase in osteoid tissues. Reducing the dose of adefovir and initiating the administration of eldecalcitol were effective for reducing proteinuria and glucosuria, and for ameliorating bone pain with an increase in serum phosphate level. This case first showed a clinical course of hypophosphatemic osteomalacia caused by secondary Fanconiʼs syndrome for 8 years after adefovir administration. Early diagnosis is important for the reversibility of bone damage and for a better renal prognosis.
Keywords adefovir dipivoxil (ADV) eldecalcitol Fanconi's syndrome hypophosphatemia osteomalacia
Amo Type Case Report
Publication Title Acta Medica Okayama
Published Date 2014-02
Volume volume68
Issue issue1
Publisher Okayama University Medical School
Start Page 53
End Page 56
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language English
Copyright Holders CopyrightⒸ 2014 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 24553490